000155448 001__ 155448
000155448 005__ 20240302115203.0
000155448 0247_ $$2pmc$$apmc:PMC8961243
000155448 0247_ $$2doi$$a10.1177/13524585211028831
000155448 0247_ $$2pmid$$apmid:34259579
000155448 0247_ $$2ISSN$$a1352-4585
000155448 0247_ $$2ISSN$$a1477-0970
000155448 0247_ $$2altmetric$$aaltmetric:109530659
000155448 037__ $$aDZNE-2021-00654
000155448 041__ $$aEnglish
000155448 082__ $$a610
000155448 1001_ $$aAly, Lilian$$b0
000155448 245__ $$aOptical coherence tomography angiography indicates subclinical retinal disease in neuromyelitis optica spectrum disorders.
000155448 260__ $$aLondon$$bSage$$c2022
000155448 3367_ $$2DRIVER$$aarticle
000155448 3367_ $$2DataCite$$aOutput Types/Journal article
000155448 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1709306031_5354
000155448 3367_ $$2BibTeX$$aARTICLE
000155448 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000155448 3367_ $$00$$2EndNote$$aJournal Article
000155448 520__ $$aNeuromyelitis optica spectrum disorders (NMOSD) are neuroinflammatory diseases of the central nervous system. Patients suffer from recurring relapses and it is unclear whether relapse-independent disease activity occurs and whether this is of clinical relevance.To detect disease-specific alterations of the retinal vasculature that reflect disease activity during NMOSD.Cross-sectional analysis of 16 patients with NMOSD, 21 patients with relapsing-remitting multiple sclerosis, and 21 healthy controls using retinal optical coherence tomography (OCT), optical coherence tomography angiography (OCT-A), measurement of glial fibrillary acidic protein (GFAP) serum levels, and assessment of visual acuity.Patients with NMOSD but not multiple sclerosis revealed lower foveal thickness (FT) (p = 0.02) measures and an increase of the foveal avascular zone (FAZ) (p = 0.02) compared to healthy controls independent to optic neuritis. Reduced FT (p = 0.01), enlarged FAZ areas (p = 0.0001), and vessel loss of the superficial vascular complex (p = 0.01) were linked to higher serum GFAP levels and superficial vessel loss was associated with worse visual performance in patients with NMOSD irrespective of optic neuritis.Subclinical parafoveal retinal vessel loss might occur during NMOSD and might be linked to astrocyte damage and poor visual performance. OCT-A may be a tool to study subclinical disease activity during NMOSD.
000155448 536__ $$0G:(DE-HGF)POF4-352$$a352 - Disease Mechanisms (POF4-352)$$cPOF4-352$$fPOF IV$$x0
000155448 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000155448 650_7 $$2Other$$aNeuromyelitis optica spectrum disorders
000155448 650_7 $$2Other$$aastrocytes
000155448 650_7 $$2Other$$abiomarker
000155448 650_7 $$2Other$$adisease activity
000155448 650_7 $$2Other$$aoptical coherence tomography angiography
000155448 650_2 $$2MeSH$$aAngiography
000155448 650_2 $$2MeSH$$aCross-Sectional Studies
000155448 650_2 $$2MeSH$$aHumans
000155448 650_2 $$2MeSH$$aNeuromyelitis Optica: diagnosis
000155448 650_2 $$2MeSH$$aRetinal Diseases
000155448 650_2 $$2MeSH$$aTomography, Optical Coherence: methods
000155448 7001_ $$aStrauß, Eva-Maria$$b1
000155448 7001_ $$aFeucht, Nikolaus$$b2
000155448 7001_ $$aWeiß, Isabella$$b3
000155448 7001_ $$aBerthele, Achim$$b4
000155448 7001_ $$aMitsdoerffer, Meike$$b5
000155448 7001_ $$0P:(DE-2719)2202037$$aHaass, Christian$$b6$$udzne
000155448 7001_ $$00000-0001-5985-6784$$aHemmer, Bernhard$$b7
000155448 7001_ $$aMaier, Mathias$$b8
000155448 7001_ $$aKorn, Thomas$$b9
000155448 7001_ $$00000-0003-4187-9472$$aKnier, Benjamin$$b10$$eCorresponding author
000155448 773__ $$0PERI:(DE-600)2008225-3$$a10.1177/13524585211028831$$gp. 135245852110288 -$$n4$$p522-531$$tMultiple sclerosis journal$$v28$$x1477-0970$$y2022
000155448 8564_ $$uhttps://journals.sagepub.com/doi/10.1177/13524585211028831?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed
000155448 8564_ $$uhttps://pub.dzne.de/record/155448/files/19537.pdf$$yOpenAccess
000155448 909CO $$ooai:pub.dzne.de:155448$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000155448 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2202037$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b6$$kDZNE
000155448 9131_ $$0G:(DE-HGF)POF4-352$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Mechanisms$$x0
000155448 9130_ $$0G:(DE-HGF)POF3-342$$1G:(DE-HGF)POF3-340$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lErkrankungen des Nervensystems$$vDisease Mechanisms and Model Systems$$x0
000155448 9141_ $$y2022
000155448 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000155448 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-16
000155448 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-16
000155448 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-16
000155448 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-01-27
000155448 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-16
000155448 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bMULT SCLER J : 2021$$d2022-11-16
000155448 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-27
000155448 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2022-11-16
000155448 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000155448 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-16
000155448 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-16
000155448 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bMULT SCLER J : 2021$$d2022-11-16
000155448 915__ $$0StatID:(DE-HGF)0430$$2StatID$$aNational-Konsortium$$d2022-11-16$$wger
000155448 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-27
000155448 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2022-11-16
000155448 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-16
000155448 9201_ $$0I:(DE-2719)1110007$$kAG Haass$$lMolecular Neurodegeneration$$x0
000155448 980__ $$ajournal
000155448 980__ $$aVDB
000155448 980__ $$aI:(DE-2719)1110007
000155448 980__ $$aUNRESTRICTED
000155448 9801_ $$aFullTexts